Christopher Degnan
Vermogen: 87 187 $ op 31-07-2026
Vermogen: 87 187 $ op 31-07-2026
Christopher Degnan currently works at UroGen Pharma Ltd., as Chief Financial & Accounting Officer from 2024.
Mr. Degnan also formerly worked at AstraZeneca PLC, as Senior Finance Director from 2004 to 2014, Endo International Plc, as Chief Financial Officer from 2016 to 2018, Endo Pharmaceuticals, Inc., as Chief Financial Officer & Vice President-Finance, Verrica Pharmaceuticals, Inc., as Chief Financial & Accounting Officer from 2018 to 2019, and Galera Therapeutics, Inc., as Chief Financial & Accounting Officer.
Mr. Degnan received his undergraduate degree from the University of Notre Dame.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-01-2026 | 2.280 ( 0% ) | 87 187 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| UROGEN PHARMA LTD. | Financieel Directeur/CFO | 08-10-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
| GALERA T COM USD0. | Financieel Directeur/CFO | 31-08-2024 |
| VERRICA PHARMACEUTICALS INC. | Financieel Directeur/CFO | 07-10-2019 |
| ENDO INTERNATIONAL PLC | Financieel Directeur/CFO | 01-03-2018 |
| ASTRAZENECA PLC | Financieel Directeur/CFO | 01-11-2014 |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Financieel Directeur/CFO | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 7 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Galera Therapeutics, Inc.
Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy | Health Technology |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures immunology, urology, hepatology, generics & sterile injectables therapeutics products | Health Technology |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
UroGen Pharma Ltd.
UroGen Pharma Ltd. BiotechnologyHealth Technology Develops therapies for urological pathologies | Health Technology |
Verrica Pharmaceuticals, Inc.
Verrica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau